Neurolutions Revenue and Competitors
Estimated Revenue & Valuation
- Neurolutions's estimated annual revenue is currently $7.8M per year.
- Neurolutions's estimated revenue per employee is $251,000
Employee Data
- Neurolutions has 31 Employees.
- Neurolutions grew their employee count by 11% last year.
Neurolutions's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO and Board Director | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Senior Director Engineering | Reveal Email/Phone |
4 | Clinical Relations Manager | Reveal Email/Phone |
5 | Clinical Manager | Reveal Email/Phone |
6 | Engineering Specialist | Reveal Email/Phone |
7 | Quality Engineer & Systems Specialist | Reveal Email/Phone |
Neurolutions Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Neurolutions?
IpsiHand is an investigational medical device that is not available for sale. The IpsiHand utilizes brain-computer interface technology to facilitate rehabilitation and improve the brain-hand connection. The device is designed for stroke patients who have lost movement in their arm and hand.
keywords:N/AN/A
Total Funding
31
Number of Employees
$7.8M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neurolutions News
2022-04-13 - 44 'breakthrough' medical devices that earned FDA approval
Neurolutions IpsiHand upper extremity rehabilitation system, manufactured by Neurolutions; Cognoa autism spectrum disorder diagnosis aid,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.7M | 31 | -35% | N/A |
#2 | N/A | 31 | 7% | N/A |
#3 | $3.5M | 31 | -14% | N/A |
#4 | $7.2M | 31 | 7% | N/A |
#5 | $4.5M | 31 | -21% | N/A |